CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

blood drawWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)

Name (Synonyms) Correlation
drug3272 fingertip tests for POC assays Wiki 0.71
drug1931 Nursing care to reduce anxiety, fear and loneliness Wiki 0.71
drug3454 saliva collection Wiki 0.71
drug3228 collection of swabs Wiki 0.71

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D007239 Infection NIH 0.04
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials

1 Renin Angiotensin System - CoronaVirus

The aim of the study is to demonstrate overactivation of Renin Angiotensine System (RAS) in positives COVID-19 patient, especially in those with the most serious clinical forms where the mortality of patients in intensive care is on average 50%. We are expecting two groups: a group of 25 positive COVID 19 patients in intensive care and a group of 25 positive COVID 19 hospitalized patients in conventional hospitalisation. We will measure RAS, serum potassium and collect data on the treatment of these patients (especially antihypertensive therapy) one week apart (at the patient'entry into hospital and 7 days later). This is a preliminary study that could possibly allow the start of a therapeutic trial in order to test the effectiveness of RAS blocker treatments in this condition.

NCT04337008 COVID 19 Other: blood draw
MeSH:Coronavirus Infections

Primary Outcomes

Description: demonstrate overactivity of RAS in patients hospitalised in intensive car secondary to COVID-19 compared to control patients (COVID -19 hospitalised patients without complications ).

Measure: overactivity of the renin / aldosterone system

Time: 7 days

2 COVID-19 in Baselland: Investigation and Validation of Serological Diagnostic Assays and Epidemiological Study of Sars-CoV-2 Specific Antibody Responses (SERO-BL-COVID-19)

The study is to investigate the antibody response in the blood and saliva of people with a known COVID-19 infection in the canton of Baselland.

NCT04483908 COVID-19 Infection Diagnostic Test: blood draw Diagnostic Test: fingertip tests for POC assays Diagnostic Test: saliva collection Diagnostic Test: collection of swabs
MeSH:Infection

Primary Outcomes

Description: Qualitative method validation: qualitative result of the ELISA (Patient does / does not have immunity) as the gold standard compared to the POC using univariate measures to derive sensitivity and specificity of the POC.

Measure: Qualitative method validation (yes/ no)

Time: at baseline

Description: Quantitative method validation: antibody concentration from the ELISA are related to the dichotomous result from POC.

Measure: Quantitative method validation (antibody concentrations)

Time: at baseline

Secondary Outcomes

Description: Antibody and T cell repertoires and transcriptional profiles of cells will be used to identify potential antibody and T cell clones correlated with COVID-19 protection.

Measure: Immune cell repertoire sequencing

Time: at baseline

No related HPO nodes (Using clinical trials)